IQVIA (NYSE:IQV) Stock Rating Upgraded by TD Cowen

IQVIA (NYSE:IQV) was upgraded by TD Cowen from a “hold” rating to a “buy” rating in a note issued to investors on Monday. The brokerage currently has a $213.00 price objective on the medical research company’s stock. TD Cowen’s target price points to a potential upside of 22.02% from the stock’s previous close.

A number of other research firms also recently commented on IQV. UBS Group decreased their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Citigroup reduced their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on IQVIA in a report on Friday, February 6th. Truist Financial cut their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Finally, Evercore restated an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $229.13.

IQVIA Trading Down 2.2%

Shares of IQV opened at $174.56 on Monday. IQVIA has a 1 year low of $134.65 and a 1 year high of $247.04. The company has a 50 day simple moving average of $207.22 and a two-hundred day simple moving average of $207.58. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market cap of $29.62 billion, a P/E ratio of 22.21, a price-to-earnings-growth ratio of 1.68 and a beta of 1.39.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. During the same period last year, the company posted $3.12 earnings per share. IQVIA’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities analysts expect that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Trading of IQVIA

Several hedge funds and other institutional investors have recently bought and sold shares of IQV. Claret Asset Management Corp increased its position in IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after acquiring an additional 49 shares during the last quarter. Versant Capital Management Inc boosted its stake in shares of IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. boosted its stake in shares of IQVIA by 3.3% during the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after purchasing an additional 58 shares during the period. Quadrant Capital Group LLC grew its holdings in IQVIA by 1.3% during the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after purchasing an additional 60 shares during the last quarter. Finally, Brookstone Capital Management raised its position in IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.